Agency claims ID NOW may return false negative results; Abbott says some studies are investigating the test's role in ways it was not meant to be used.
Transcatheter structural heart therapies stand to replace their open-heart counterparts thanks to technological innovations and expanded patient access.
The start of the '20s offers the industry an opportunity to build value through new tech., collaborations, clinical validations, and value-based outcomes.